Cargando…
Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective
Multiple genetic abnormalities will have occurred in advanced cervical cancer and multiple targeting is likely to be needed to control tumor growth. To date, dominant therapeutic targets under scrutiny for cervical cancer treatment have been EGFR pathway and angiogenesis inhibition as well as anti-H...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195803/ https://www.ncbi.nlm.nih.gov/pubmed/22091418 http://dx.doi.org/10.5402/2011/403098 |
_version_ | 1782214165842100224 |
---|---|
author | Scholl, Susy M. E. Kenter, Gemma Kurzeder, Christian Beuzeboc, Philippe |
author_facet | Scholl, Susy M. E. Kenter, Gemma Kurzeder, Christian Beuzeboc, Philippe |
author_sort | Scholl, Susy M. E. |
collection | PubMed |
description | Multiple genetic abnormalities will have occurred in advanced cervical cancer and multiple targeting is likely to be needed to control tumor growth. To date, dominant therapeutic targets under scrutiny for cervical cancer treatment have been EGFR pathway and angiogenesis inhibition as well as anti-HPV vaccines. The potentially most effective targets to be blocked may be downstream from the membrane receptor or at the level of the nucleus. Alterations of the pathways involved in DNA repair and in checkpoint activations, as well as the specific site of HPV genome integration, appear worth assessing. For genetic mutational analysis, complete exon sequencing may become the norm in the future but at this stage frequent mutations (that matter) can be verified by PCR analysis. A precise documentation of relevant alterations of a large spectrum of protein biomarkers can be carried out by reverse phase protein array (RPPA) or by multiplex analysis. Clinical decision-making on the drug(s) of choice as a function of the biological alteration will need input from bio-informatics platforms as well as novel statistical designs. Endpoints are yet to be defined such as the loss (or reappearance) of a predictive biomarker. Single or dual targeting needs to be explored first in relevant preclinical animal and in xenograft models prior to clinical deployment. |
format | Online Article Text |
id | pubmed-3195803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | International Scholarly Research Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-31958032011-11-16 Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective Scholl, Susy M. E. Kenter, Gemma Kurzeder, Christian Beuzeboc, Philippe ISRN Oncol Review Article Multiple genetic abnormalities will have occurred in advanced cervical cancer and multiple targeting is likely to be needed to control tumor growth. To date, dominant therapeutic targets under scrutiny for cervical cancer treatment have been EGFR pathway and angiogenesis inhibition as well as anti-HPV vaccines. The potentially most effective targets to be blocked may be downstream from the membrane receptor or at the level of the nucleus. Alterations of the pathways involved in DNA repair and in checkpoint activations, as well as the specific site of HPV genome integration, appear worth assessing. For genetic mutational analysis, complete exon sequencing may become the norm in the future but at this stage frequent mutations (that matter) can be verified by PCR analysis. A precise documentation of relevant alterations of a large spectrum of protein biomarkers can be carried out by reverse phase protein array (RPPA) or by multiplex analysis. Clinical decision-making on the drug(s) of choice as a function of the biological alteration will need input from bio-informatics platforms as well as novel statistical designs. Endpoints are yet to be defined such as the loss (or reappearance) of a predictive biomarker. Single or dual targeting needs to be explored first in relevant preclinical animal and in xenograft models prior to clinical deployment. International Scholarly Research Network 2011 2011-07-06 /pmc/articles/PMC3195803/ /pubmed/22091418 http://dx.doi.org/10.5402/2011/403098 Text en Copyright © 2011 Susy M. E. Scholl et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Scholl, Susy M. E. Kenter, Gemma Kurzeder, Christian Beuzeboc, Philippe Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective |
title | Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective |
title_full | Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective |
title_fullStr | Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective |
title_full_unstemmed | Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective |
title_short | Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective |
title_sort | pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195803/ https://www.ncbi.nlm.nih.gov/pubmed/22091418 http://dx.doi.org/10.5402/2011/403098 |
work_keys_str_mv | AT schollsusyme pathwayprofilingandrationaltrialdesignforstudiesinadvancedstagecervicalcarcinomaareviewandaperspective AT kentergemma pathwayprofilingandrationaltrialdesignforstudiesinadvancedstagecervicalcarcinomaareviewandaperspective AT kurzederchristian pathwayprofilingandrationaltrialdesignforstudiesinadvancedstagecervicalcarcinomaareviewandaperspective AT beuzebocphilippe pathwayprofilingandrationaltrialdesignforstudiesinadvancedstagecervicalcarcinomaareviewandaperspective |